PLSE News

Latest breaking news and updates for PLSE stock.

Track all markets on TradingView

Pulse Biosciences Announces First Successful Procedures in PRECISE Benign Thyroid Nodule (BTN) Study

(NASDAQ:PLSE) HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) t...

How does Pulse Biosciences' nanosecond PFA technology compare to existing treatments for benign thyroid nodules and any competitive threats? What is the expected timeline for additional data releases or potential FDA clearance for the nsPFA™ system in thyroid indications? How will the successful first procedures in the PRECISE-BTN study affect Pulse Biosciences' short‑term stock performance?
Clinical trials
4 days ago
Read more businesswire

Pulse Biosciences Announces Publication of First-In-Human Data for Treatment of Benign Thyroid Nodules in the Journal Thyroid

HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) technology, tod...

What regulatory milestones, reimbursement timelines, and market adoption risks should be considered when assessing the long-term impact of this publication on PLSE's stock performance? What are the potential competitive advantages or disadvantages of Pulse's nanosecond PFA technology compared to existing thyroid ablation methods and other companies' pipeline therapies? How will the first-in-human efficacy and safety data for nsPFA in benign thyroid nodules influence Pulse Biosciences' valuation and revenue projections?
Clinical trials
11 days ago
Read more businesswire

Pulse Biosciences Reports Business Updates and Second Quarter 2025 Financial Results

HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) technology, tod...

What risk factors were highlighted in the earnings release (e.g., regulatory risk, technology adoption risk, reimbursement uncertainty) that could affect the valuation? Are there any upcoming catalyst events (e.g., data readouts, regulatory submissions, investor presentations) that could drive volatility in PLSE stock? What is the anticipated impact on the share price in the near term, given the sentiment score of 60 and the market's reaction to previous earnings releases?
Earnings
25 days ago
Read more businesswire